What insurance policy changes affect CPT 83497?

There are 5 tracked policy changes affecting CPT 83497, including updates from Aetna, Healthfirst, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 83497?

Payers that have issued tracked updates for CPT 83497 include: Aetna, Healthfirst, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 83497 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 83497. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for CPT 83497?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

83497 Insurance Policy Changes

CPT 83497 is referenced in 5 tracked payer policy changes from Aetna, Healthfirst, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 83497 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Effective Jan 1, 2026Medium impact
Gout (CPB 0810, reviewed 2026-03-27)
Aetna's Clinical Policy Bulletin 0810 for gout applies to commercial medical plans and was last reviewed 03/27/2026. Pegloticase (Krystexxa) is covered for chronic gout in members 18 or older who meet the initial approval criteria, and for continuing therapy when the continuation criteria are met. Oral urate-lowering therapy cannot be used at the same time as pegloticase. The Site of Care Utilization Management Policy applies to pegloticase beginning January 1, 2026. Pegloticase is considered experimental, investigational, or unproven for all other indications, including asymptomatic hyperuricemia and G6PD deficiency. Blood uric acid measurement, erythrocyte sedimentation rate, polarized light microscopy of synovial fluid, and MRI for gouty tophus are considered medically necessary for managing gout.
Healthfirst · Effective Jan 1, 2026Medium impact
Provider Updates for May 2026
Healthfirst's Diagnosis of Idiopathic Environmental Intolerance policy (PO-RE-065v6) states that laboratory tests designed to confirm idiopathic environmental intolerance do not meet coverage criteria in all circumstances. For asymptomatic individuals and during general encounters without abnormal findings, screening and profiling tests for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides, carnitine, oxidative stress, vitamin, mineral, nutritional and metals testing also do not meet coverage criteria, and breath hydrogen and/or breath methane testing does not meet coverage criteria in any circumstances. The description for CPT codes 83015 and 83018 was revised effective 1/1/2026.
Aetna · Identified Aug 19, 2026Medium impact
Nonstandard Laboratory Test Panels (CPB 0499, reviewed 2026-08-03)
Aetna considers laboratory test panels experimental, investigational, or unproven when they include nonstandard tests that have no proven value. Panels are also considered experimental, investigational, or unproven when they include standard tests performed for persons without specific signs and symptoms warranting the test, or for indications that are not established. The policy names panels and tests from Aeron Life Cycles, Alletess Medical Laboratory, BioHealth, DiagnosTechs, Doctor's Data Lab, Great Plains Laboratory, Moleculera Labs, Physicians Lab and ZRT Laboratory as experimental, investigational, or unproven, and it lists other laboratories that perform non-standard panels considered experimental, investigational, or unproven. Certain tests are considered medically necessary in specific situations, such as urine porphyrins for persons with signs and symptoms of porphyria. There is no evidence that these laboratory test panels affect the management of afflicted individuals.
Aetna · Identified Aug 16, 2026Medium impact
Lyme Disease and other Tick-Borne Diseases (CPB 0215, reviewed 2026-07-21)
Aetna considers outpatient IV antibiotic therapy medically necessary for Lyme disease only when the clinical presentation is compatible with the disease and supported by two-tier serologic testing. Once Lyme disease is definitively diagnosed, an initial 4-week course of outpatient IV antibiotic therapy is medically necessary for persistent Lyme arthritis after failing a 4-week course of oral antibiotics, for moderate-to-severe cardiac or neurologic involvement, and for specified cases in pregnant women, and one repeat 4-week course is medically necessary with objective evidence of relapse, progression of organ damage, or a new focus or type of organ damage. Aetna considers IV antibiotic therapy for early Lyme disease, additional antibiotic therapy for post-treatment persistently fatigued patients, and a range of listed tests and treatments experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Organic Acid Testing
Screening for organic acid disorders may be considered medically necessary in symptomatic newborns and infants. Organic acid testing is considered not medically necessary for all other indications, including fatigue, sleep abnormalities, mood changes, blood sugar dysregulation, weight gain, nausea, multiple chemical sensitivity, bloating, distention, joint pain, gas, reflux, autoimmune disorders, dermatitis, depression, anxiety, cancer, inflammation, headaches and early aging.

Watch 83497

Get one email when a payer policy names 83497, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Gout (CPB 0810, reviewed 2026-03-27)

Provider Updates for May 2026

Nonstandard Laboratory Test Panels (CPB 0499, reviewed 2026-08-03)

Lyme Disease and other Tick-Borne Diseases (CPB 0215, reviewed 2026-07-21)

Organic Acid Testing

What insurance policy changes affect CPT 83497?

Which payers have updated policy for CPT 83497?

How do I get notified when CPT 83497 policy changes?

Why do payers change policies for CPT 83497?